• Last patient dosed in SPL026-SSRI drug interaction study with data readout anticipated in Q3 2023 • Potential for an…
Tinlarebant (a/k/a LBS-008) is Belite Bio’s orally administered tablet intended to slow disease progression in subjects with Stargardt Disease (STGD1)…
NOVATO, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development…
Exercise of Procurement Options of Approximately $113 Million for Oral TPOXX and Approximately $25 Million for IV TPOXX under Current…
Cash and cash equivalents at €31.2 million, short-term deposits at €0.05 million2, and long-term deposit at €9.3 million3 as of…
BOSTON, July 27, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel…
Appointment adds Dr. Powchik’s experience in the development of marketed immunotherapeutics to Vaxxinity’s leadership team CAPE CANAVERAL, Fla., July 27,…
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on…
HAMBURG, GERMANY / ACCESSWIRE / July 27, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced…
Widely considered the industry’s highest accolade for pharmaceutical research and development, the Prix Galien rewards innovative treatments and technologies that…